Blinatumomab use in pediatric B-ALL: where are we now?
Abstract: Blinatumomab, a bispecific T-cell–engager antibody construct targeting CD19, has emerged as a transformative therapy in B-cell acute lymphoblastic leukemia (B-ALL) in both adult and pediatric populations. In pediatric populations, blinatumomab has demonstrated efficacy both in patients wit...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925003210 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|